童向民 (Xiangmin Tong)

institute of biophysics chinese academy of sciences教授邮箱:tongxiangmin@163.com

H指数:33

被引数:4,853

个人简介

"教育背景\n·博士：2008 年9 月-2012 年7 月，浙江大学，临床医学；·访问学者：2009 年1 月-2009 年10 月，德国基尔大学，临床医学；·硕士：2000 年9 月-2003 年7 月，浙江大学，临床医学；·学士：1988 年9 月-1993 年7 月，浙江大学，临床医学。\n学术任职\n·中华医学会血液学分会全国青年委员；·中国民族医药学会血液病分会常务理事；·中国老年医学学会检验医学分会常务委员；·浙江省医学会精准医学分会副主任委员；·中国抗癌协会肿瘤精准治疗专业委员会委员；·中华医学会医学科学研究管理学分会委员；·浙江省中西医结合学会第三节血液病专业委员会副主任委员；·浙江省医学会临床试验与伦理分会第一届委员会副主任委员。\n主持项目\n1.免疫与基因治疗新技术研究及药物开发-靶向原癌基因RON 抗体-美登素偶联物H-Zt/g4-DM1 治疗大肠癌及肝转移临床前研究，浙江省科技厅重点研发项目，2019 年-2021 年；2.治疗结肠癌中药一类新药TEOA 的临床前研究，国家卫健委新药创制重大专项，2018 年-2021 年；3.益气养阴方及拆方通过招募治疗影响AML 干细胞归巢的研究，浙江省中医药管理局（重点），2017 年-2020 年；4.基于microRNA-34a 和let-7 信号通路的基因病毒治疗在弥漫大B 细胞淋巴瘤中的作用及机制研究，国家自然科学基金面上项目，2016 年-2019 年；5.基于SVM 技术优化AML 微小残留灶的分析及临床应用，浙江省科技厅重大科技专项，2012 年-2015 年；6.原癌基因RON 参与EB 病毒感染的霍奇金淋巴瘤发病及其药靶效应，国家自然科学基金面上项目，2011 年-2014 年。\n发表论文\n1、Shuangshuang Li, Xiangli Gao, Xiaoxin Wu, Zhigang Wu, Linfang Cheng, Lifen Zhu, Dan Shen, Xiangmin Tong. Parthenolide inhibits LPS-induced inflammatory cytokines through the toll-like receptor 4 signal pathway in THP-1 cells. Acta Biochim Biophys Sin (Shanghai). 2015, 47(5): 368-375.2、Qiaojuan Zhu, Yazhao Li, Yang Guo, Linjun Hu, Zunqiang Xiao, Xin Liu, Jiahui Wang, Qiuran Xu, Xiangmin Tong, Long non-coding RNA SNHG16 promotes proliferation and inhibits apoptosis of diffuse large B-cell lymphoma cells by targeting MIR-497-5P/PIM1 axis. Journal of Cellular and Molecular Medicine. 2019, 23(11): 7395-7405.3、Linjun Hu, Yuling Gao, Zhan Shi, Yang Liu, Junjun Zhao, Zunqiang Xiao, Jiayin Lou, Qiuran Xu, Xiangmin Tong, DNA methylation-based prognostic biomarkers of acute myeloid leukemia patients, Annals of Translational Medicine, 2019, 7(23): 737.4、Fan Ni, Xianbo Huang, Zhenzhen Chen, Wenbin Qian, Xiangmin Tong. Shikonin exerts antitumor activity in Burkitt’s lymphoma by inhibiting C-MYC and PI3K/AKT/mTOR pathway and acts synergistically with doxorubicin. Scientific Reports, 2018, 8: 3317.5、Yu Chen, Tongtong Wang, Jing Du, Yanchun Li, Xin Wang,Yi Zhou, XingXing Yu, Weimin Fang, Qiaojuan Zhu, Xiangmin Tong, Ying Wang. The Critical Role of PTEN/PI3K/AKT Signaling Pathway in Shikonin-Induced Apoptosis and Proliferation Inhibition of Chronic Myeloid Leukemia. Cellular Physiology and Biochemistry. 2018, 47, 981-993.6、Qiuran Xu, Changwei Dou, Xin Liu, Liu Yang, Chao Ni, Jiahui Wang, Yang Guo, Wei Yang, Xiangmin Tong, Dongsheng Huang. Oviductus ranae protein hydrolysate (ORPH) inhibits the growth, metastasis and glycolysis of HCC by targeting miR-491-5p/PKM2 axis. Biomedicine & Pharmacotherapy. 2018, 107, 1692-1704.7、Qiuran Xu, Qiaojuan Zhu, Zhenyu Zhou, Yufeng Wang, Xin Liu, Guozhi Yin, Xiangmin Tong, Kangsheng Tu. MicroRNA-876-5p inhibits epithelialmesenchymal transition and metastasis of hepatocellular carcinoma by targeting BCL6 corepressor like 1. Biomedicine & Pharmacotherapy. 2018, 103, 645-652.8、Jiamin Peng, Shibing Wang, Weimin Fan, Shuangshuang Li, Yi Wu, Xiaozhou Mou, Jianchao Wang, Xiangmin Tong, Synergistic suppression effect on tumor growth of acute myeloid leukemia by combining cytarabine with an engineered oncolytic vaccinia virus. OncoTargets and Therapy. 2018:6887–6900.9、Xiang-Min Tong, Liang Feng, Sreedhar Reddy Suthe, Tian-Hao Weng, Chen-Yu Hu, Yi-Zhi Liu, Zhi-Gang Wu, Ming-Hai Wang, Hang-Ping Yao. Therapeutic efficacy of a novel humanized antibody-drug conjugate recognizing plexin-semaphorin-integrin domain in the RON receptor for targeted cancer therapy. J Immunother Cancer. 2019, 7(1):250.10、Hang-Ping Yao, Liang Feng, Sreedhar Reddy Suthe, Ling-Hui Chen, Tian-Hao Weng,1 Chen-Yu Hu, Eun Sung Jun, Zhi-Gang Wu, Wei-Lin Wang, Song Cheol Kim, Xiang-Min Tong, Ming-Hai Wang. Therapeutic efficacy, pharmacokinetic profiles, and toxicological activities of humanized antibody-drug conjugate Zt/g4-MMAE targeting RON receptor tyrosine kinase for cancer therapy. J Immunother Cancer. 2019, 7, 75."